Beacon Biosignals Expands Series B to $97M, Advancing AI-Powered Neurotechnology for Brain Health

April 6,Boston, Beacon Biosignals announced the extension of its Series B financing, bringing the total raised in this round to $97 million, with cumulative funding exceeding $132 million. The expanded round includes new investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next.

This financing builds on Beacon's previously announced $86 million Series B round, led by a consortium of leading healthcare and technology investors, including Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, Indicator Ventures, and others.

The new capital will further accelerate Beacon's mission to transform brain health through scalable at-home EEG and advanced analytics, powering the next generation of diagnostics, clinical trials, and precision medicine.

Jacob Donoghue, CEO of Beacon Biosignals, stated:"This milestone reflects the strong momentum behind our vision to make brain health measurable, scalable, and actionable. We are deeply grateful for the support of both new and existing investors as we build the future of brain health."

Daniel Goldberg, Managing Director of Palo Santo, stated:"Beacon Biosignals has a unique advantage in unlocking the potential of large-scale brain data. By combining clinical-grade EEG with advanced analytics, they are ushering in a new era of neuroscience discovery and precision. As novel therapies like psychedelics reshape the treatment landscape for mental health disorders, platforms like Beacon are essential for objectively measuring brain-based outcomes and accelerating development."

Beacon Biosignals is harnessing the power of brain data to advance human health. The company combines FDA-approved wearable EEG technology with advanced artificial intelligence to capture and analyze real-world neural data, driving breakthroughs in neurology, psychiatry, and sleep medicine. The Beacon platform provides clinicians and biopharmaceutical partners with objective measurements of brain function to accelerate research, improve diagnostics, and guide new treatment approaches.